News & Events
Crinetics Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an aggregate of 9,950 restricted stock unit awards to 14 new non-executive employees.
READ MORECrinetics Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new non-executive employees.
READ MORECrinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics announces positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of atumelnant, a candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome.
READ MORECrinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Crinetics to present at the 43rd Annual J. P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 14, 2025 at 4:30 p.
READ MORECrinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
Crinetics announces the appointment of Isabel Kalofonos as Chief Commercial Officer to lead global commercial strategy for the company’s first drug launch and its innovative pipeline of candidates.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
